BRPI0608273A2 - peptìdeos para diminuição da pressão sanguìnea a partir de glicomacropeptìdeo - Google Patents

peptìdeos para diminuição da pressão sanguìnea a partir de glicomacropeptìdeo

Info

Publication number
BRPI0608273A2
BRPI0608273A2 BRPI0608273-4A BRPI0608273A BRPI0608273A2 BR PI0608273 A2 BRPI0608273 A2 BR PI0608273A2 BR PI0608273 A BRPI0608273 A BR PI0608273A BR PI0608273 A2 BRPI0608273 A2 BR PI0608273A2
Authority
BR
Brazil
Prior art keywords
proline
glycomacropeptide
blood pressure
protein
protein source
Prior art date
Application number
BRPI0608273-4A
Other languages
English (en)
Inventor
Roos Andre Leonardus De
Den Broecke Pieter Marinus Van
Luppo Edens
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of BRPI0608273A2 publication Critical patent/BRPI0608273A2/pt
Publication of BRPI0608273B1 publication Critical patent/BRPI0608273B1/pt
Publication of BRPI0608273B8 publication Critical patent/BRPI0608273B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PEPTìDEOS PARA DIMINUIçãO DA PRESSãO SANGUìNEA A PARTIR DE GLICOMACROPEPTìDEO. Um processo para produzir IPP a partir de uma fonte de proteína, pelo que a fonte de proteína compreende uma proteína tendo a seqúência -I-P-P- e tendo, na seqúência de aminoácido da proteína, pelo menos 6 vezes mais -I-P--P-presente do que -V-P-P- (base molar), o qual compreende hidrólise da fonte de proteína para liberar pelo menos 40% da seqúência -I-P--P- no peptídeo IPP e pelo que uma enzima proteolítica é usada a qual cliva, no carbóxi-término, os resíduos de prolina presentes na fonte de proteína, a enzima é, de preferência, uma endoprotease prolina-específica ou oligopeptidase prolina-específica, mais preferivelmente uma endoprotease prolina-específica e opcionalmente uma amino peptidase.
BRPI0608273A 2005-02-24 2006-02-23 processo para produzir ipp a partir de gmp (glicomacropeptídeo de kappa caseína), composição de peptídeo e uso da mesma, bem como processo para preparar um produto alimentício, produto de bebida ou suplemento dietético BRPI0608273B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101417 2005-02-24
EP05110236 2005-11-01
PCT/EP2006/060198 WO2006089921A1 (en) 2005-02-24 2006-02-23 Blood pressure lowering peptides from glycomacropeptide

Publications (3)

Publication Number Publication Date
BRPI0608273A2 true BRPI0608273A2 (pt) 2009-12-15
BRPI0608273B1 BRPI0608273B1 (pt) 2017-04-04
BRPI0608273B8 BRPI0608273B8 (pt) 2021-07-27

Family

ID=36061583

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608273A BRPI0608273B8 (pt) 2005-02-24 2006-02-23 processo para produzir ipp a partir de gmp (glicomacropeptídeo de kappa caseína), composição de peptídeo e uso da mesma, bem como processo para preparar um produto alimentício, produto de bebida ou suplemento dietético

Country Status (12)

Country Link
US (1) US8088597B2 (pt)
EP (1) EP1851323B1 (pt)
JP (1) JP5770411B2 (pt)
KR (1) KR101244995B1 (pt)
CN (2) CN101128596B (pt)
AU (1) AU2006217901B2 (pt)
BR (1) BRPI0608273B8 (pt)
EA (1) EA016396B1 (pt)
ES (1) ES2599859T3 (pt)
NZ (1) NZ560601A (pt)
PL (1) PL1851323T3 (pt)
WO (1) WO2006089921A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523410A1 (en) 2003-05-05 2004-11-18 Unilever Plc Hydrolysed casein product comprising tripeptides ipp and/or vpp
CN101084004A (zh) * 2004-12-22 2007-12-05 帝斯曼知识产权资产管理有限公司 单个酶促步骤中的血压降低寡肽
EP1874129A1 (en) * 2005-04-28 2008-01-09 Unilever PLC Peptides having an ace inhibiting effect
WO2009057725A1 (ja) * 2007-10-31 2009-05-07 Ito En, Ltd. 蛋白質分解酵素処理モロヘイヤ抽出物組成物とその製造方法及び該組成物を含む血圧降下剤又は飲食物
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
CA2784944A1 (en) * 2009-12-21 2011-06-30 Centre Hospitalier Universitaire Vaudois Synergic action of a prolyl protease and tripeptidyl proteases
AU2015334890B2 (en) * 2014-10-24 2021-12-23 Dupont Nutrition Biosciences Aps Proline tolerant tripeptidyl peptidases and uses thereof
US11129404B2 (en) 2015-12-28 2021-09-28 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof
JP6967404B2 (ja) * 2017-08-31 2021-11-17 雪印メグミルク株式会社 アッカーマンシア・ムシニフィラ増加促進用組成物
JP6993142B2 (ja) * 2017-08-31 2022-01-13 雪印メグミルク株式会社 アッカーマンシア・ムシニフィラ増加促進用組成物
CN109380728B (zh) * 2018-10-17 2022-03-22 汤臣倍健股份有限公司 一种具有辅助降血压功效的组合物及保健食品
US11825860B1 (en) 2023-01-13 2023-11-28 Leprino Foods Company Denatured milk proteins and methods of making them

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311051A1 (de) * 1983-03-25 1984-09-27 Siemens AG, 1000 Berlin und 8000 München Flexibles heizelement in bandform, das aus elektrisch leitfaehigen koernchen aus ptc-material und einem organischen isolierenden kunststoff als bindemittel besteht, und verfahren zur herstellung des flexiblen heizelementes
JP2622686B2 (ja) * 1987-05-15 1997-06-18 雪印乳業株式会社 k−カゼイングリコマクロペプチドの製造法
JPH01291795A (ja) * 1988-05-18 1989-11-24 Takara Shuzo Co Ltd プロリン残基特異的ペプチダーゼの製造方法
JP2673828B2 (ja) * 1989-04-19 1997-11-05 雪印乳業株式会社 κ―カゼイングリコマクロペプチドの製造法
JP2920427B2 (ja) * 1991-01-21 1999-07-19 雪印乳業株式会社 κ−カゼイングリコマクロペプチドの製造法
DK8892D0 (da) * 1992-01-23 1992-01-23 Symbicom Ab Humant proteingen
US5391497A (en) * 1992-10-13 1995-02-21 University Of Colorado Foundation, Inc. Human k-casein
JPH06345664A (ja) * 1993-06-11 1994-12-20 Takako Tomita 新規な血圧上昇抑制用組成物
JP3567012B2 (ja) * 1995-03-28 2004-09-15 雪印乳業株式会社 新規ペプチド及びその利用
JPH09164A (ja) * 1995-06-22 1997-01-07 Asahi Chem Ind Co Ltd 加水分解蛋白質の製造方法
JPH1033115A (ja) * 1996-07-24 1998-02-10 Nouchikusangiyou Shinko Jigyodan ホエー飲料とその製造法
WO1998014071A1 (en) * 1996-10-01 1998-04-09 John Stephen Ayers Process for isolating glycomacropeptide from dairy products with a phenylalanine impurity of 0.5 %w/w
US6323008B1 (en) * 1997-08-14 2001-11-27 Neose Technologies, Inc. Methods for producing sialyloligosaccharides in a dairy source
JP4727770B2 (ja) * 1997-09-26 2011-07-20 カルピス株式会社 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びFischer比低下の少なくとも1つの軽減剤
US6168823B1 (en) * 1997-10-09 2001-01-02 Wisconsin Alumni Research Foundation Production of substantially pure kappa casein macropeptide
US5968586A (en) * 1997-10-09 1999-10-19 Wisconsin Alumni Research Foundation Production of κ-casein macropeptide for nutraceutical uses
FI113741B (fi) * 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
JP4633876B2 (ja) * 1999-11-11 2011-02-16 カルピス株式会社 トリペプチドの製造方法
AU2002234561B2 (en) * 2000-12-07 2007-01-18 Dsm Ip Assets B.V. Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
JP4815568B2 (ja) * 2001-01-05 2011-11-16 独立行政法人産業技術総合研究所 好熱性プロリルエンドペプチダーゼ
DE10149668A1 (de) * 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
US20050256057A1 (en) * 2002-06-04 2005-11-17 Luppo Edens Protein hydrolysate rich in tripeptides
CA2523410A1 (en) * 2003-05-05 2004-11-18 Unilever Plc Hydrolysed casein product comprising tripeptides ipp and/or vpp
CN100439393C (zh) * 2003-08-01 2008-12-03 卡尔皮斯株式会社 生物体内非分解性肽、血管紧张素转换酶抑制剂、药物和功能性食品
MXPA06010014A (es) * 2004-03-01 2007-03-07 Peptera Pharmaceuticals Ltd Peptidos derivados de la caseina y usos terapeuticos de los mismos.
US20070207944A1 (en) * 2004-07-12 2007-09-06 Luppo Edens Blood Pressure Lowering Oligopeptides

Also Published As

Publication number Publication date
JP5770411B2 (ja) 2015-08-26
BRPI0608273B1 (pt) 2017-04-04
KR101244995B1 (ko) 2013-03-18
US8088597B2 (en) 2012-01-03
AU2006217901B2 (en) 2011-09-29
BRPI0608273B8 (pt) 2021-07-27
KR20070114141A (ko) 2007-11-29
ES2599859T3 (es) 2017-02-03
EP1851323B1 (en) 2016-09-28
EA016396B1 (ru) 2012-04-30
CN101128596A (zh) 2008-02-20
CN103463615B (zh) 2016-09-07
CN103463615A (zh) 2013-12-25
JP2008537476A (ja) 2008-09-18
CN101128596B (zh) 2014-07-23
NZ560601A (en) 2009-09-25
PL1851323T3 (pl) 2017-02-28
AU2006217901A1 (en) 2006-08-31
EA200701778A1 (ru) 2008-02-28
US20080161227A1 (en) 2008-07-03
WO2006089921A1 (en) 2006-08-31
EP1851323A1 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
BRPI0608273A2 (pt) peptìdeos para diminuição da pressão sanguìnea a partir de glicomacropeptìdeo
BRPI0513237A (pt) hidrolisados de proteìna para diminuição de pressão sanguìnea
ES2551711T3 (es) Proceso de maceración
BR0207325A (pt) Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1
BRPI0314814B8 (pt) anticorpo compreendendo uma variante de fc
BRPI0416546A (pt) produção de ácido 3-hidroxipropiÈnico usando beta-alanina/piruvato aminotransferase
BRPI0519172A2 (pt) proteÍna mutante, polinucleotÍdeo, microorganismo transformado, e, mÉtodos de produzir uma proteÍna mutante, um peptÍdeo, e alfa-l-aspartil-l-fenilalanina-beta-Éster, e de projetar e produzir uma proteÍna mutante
BRPI0416544A (pt) proteìna de ligação de gag
WO2004050825A3 (en) Protein synthesis monitoring (psm)
BRPI0515760A (pt) proteìnas de fusão
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
BR0208207A (pt) Redução da imunogenicidade das proteìnas de fusão
ATE441313T1 (de) Vorschaltgerät für mindestens eine hochdruckentladungslampe, betriebsverfahren und beleuchtungssystem für eine hochdruckentladungslampe
AR048599A1 (es) Anticuerpos anti-p-selectina
BRPI0607097A2 (pt) peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada
WO2006067163A3 (en) Blood pressure lowering oligopeptides in a single enzymatic step
AR063239A1 (es) Procedimiento para la generacion de proteina y usos de la misma
CL2009001376A1 (es) Reactor de hidrolisis; donde en las salidas del reactor se disponen varios tornillos reversibles; y un rectangulo para la separacion de colageno.
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0211285A (pt) Concentrado de inibidor bowman-birk de alta proteìna e processo para sua produção
BR112017008304A2 (pt) tripeptidil peptidases tolerantes à prolina e seus usos
BR112021016727A2 (pt) Hidrolisados de proteína com rendimento aumentado de aminoácido n-terminal
BR0213583A (pt) Processo para preparar um composto de insulina, e, composto de insulina
DE60335726D1 (de) Chromoprotein und fluoroproteine
BRPI9910445B8 (pt) preparação farmacêutica na forma de comprimido, bem como seu processo de produção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12P 21/02 , C12P 21/06

Ipc: C12P 21/02 (2006.01), C12P 21/06 (2006.01), A61K 3

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2763 DE 19-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.